1. A class action lawsuit has been filed against Capricor Therapeutics. 2. The lawsuit claims CAPR misled investors about its drug deramiocel. 3. Investors purchased CAPR securities at inflated prices. 4. Damaging information was intentionally concealed from investors. 5. Shareholders may participate in the class action lawsuit.
The allegations of misleading investors can significantly erode confidence, leading to price drops. Historical cases of similar lawsuits often resulted in substantial declines in stock values.
The lawsuit could directly influence investor trust and trading behavior, especially given CAPR’s clinical stage. Legal issues often divert focus from business development, impacting stock performance.
The lawsuit's immediate effects can result in rapid stock price adjustments as investor sentiment shifts. Past examples show that litigation news can impact prices quickly, within weeks or months.
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ:CAPR) between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company.
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Capricor Therapeutics, Inc. (NASDAQ:CAPR) Misled Investors Regarding its Business Operations.
According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning deramiocel, Capricor's lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Further, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. The lawsuit alleges this caused shareholders to purchase Capricor's securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Capricor Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 15, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250906643675/en/
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com